U.S. bank Wells Fargo has suspended all travel to China after one of its employees was barred from leaving the country, a ...

Following a successful patent defense case upheld by China’s IP authority, AstraZeneca invested nearly 9 billion yuan ($1.24 billion) to establish two global R&D centres in Beijing and Shanghai, said ...

Sino Biopharmaceuticals plans to pay up to $950.9 million to acquire LaNova Medicines, which previously licensed drugs to ...

BEIJING: US bank Wells Fargo told AFP Friday it was working to help one of its employees return to the United States, after ...

Top regulators like the US FDA and EMA are fast-tracking more Chinese drugs, granting priority review and breakthrough ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said ...

Biotech deals involving assets developed in China are surging, a Jefferies report shows. | Biotech deals involving assets ...

Both AstraZeneca and MSD have tied lucrative licensing deals for two of LaNova’s oncology assets in recent years.

HONG KONG] The biotechnology industry is experiencing a tectonic shift, driven by Chinese drugmakers who have come a long way ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Sino Biopharm will buy the 95.1 percent of the Chinese developer of novel biologic drugs for cancer treatment that it does not already own, the Beijing-based company announced late on July 15. LaNova ...

Hong Kong-based Sino Biopharm, which took its stake in LaNova when it participated in the company's $42 million financing ...